Literature DB >> 11039575

Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.

L Sarantaus1, P Huusko, H Eerola, V Launonen, P Vehmanen, K Rapakko, E Gillanders, K Syrjäkoski, T Kainu, P Vahteristo, R Krahe, K Pääkkönen, J Hartikainen, C Blomqvist, T Löppönen, K Holli, M Ryynänen, R Bützow, A Borg, B Wasteson Arver, E Holmberg, A Mannermaa, J Kere, O P Kallioniemi, R Winqvist, H Nevanlinna.   

Abstract

In the Finnish breast and ovarian cancer families six BRCA1 and five BRCA2 mutations have been found recurrently. Some of these recurrent mutations have also been seen elsewhere in the world, while others are exclusively of Finnish origin. A haplotype analysis of 26 Finnish families carrying a BRCA1 mutation and 20 families with a BRCA2 mutation indicated that the carriers of each recurrent mutation have common ancestors. The common ancestors were estimated to trace back to 7-36 generations (150-800 years). The time estimates and the geographical clustering of these founder mutations in Finland are in concordance with the population history of this country. Analysis of the cancer phenotypes showed differential ovarian cancer expression in families carrying mutations in the 5' and 3' ends of the BRCA1 gene, and earlier age of ovarian cancer onset in families with BRCA1 mutations compared with families with BRCA2 mutations. The identification of prominent and regional BRCA1 and BRCA2 founder mutations in Finland will have significant impact on diagnostics in Finnish breast and ovarian cancer families. An isolated population with known history and multiple local founder effects in multigenic disease may offer distinct advantages also for mapping novel predisposing genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11039575     DOI: 10.1038/sj.ejhg.5200529

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  27 in total

Review 1.  Finnish Disease Heritage I: characteristics, causes, background.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

Review 2.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

3.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.

Authors:  Hélène Vézina; Francine Durocher; Martine Dumont; Louis Houde; Csilla Szabo; Martine Tranchant; Jocelyne Chiquette; Marie Plante; Rachel Laframboise; Jean Lépine; Heli Nevanlinna; Dominique Stoppa-Lyonnet; David Goldgar; Peter Bridge; Jacques Simard
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

4.  Identification of a founder BRCA2 mutation in Sardinian breast cancer families.

Authors:  Maria Monne; Giovanna Piras; Patrizia Fancello; Maria Cristina Santona; Antonella Uras; Gennaro Landriscina; Giuseppe Mastio; Attilio Gabbas
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

5.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

6.  A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.

Authors:  Liisa M Pelttari; Johanna Kiiski; Riikka Nurminen; Anne Kallioniemi; Johanna Schleutker; Alexandra Gylfe; Lauri A Aaltonen; Arto Leminen; Päivi Heikkilä; Carl Blomqvist; Ralf Bützow; Kristiina Aittomäki; Heli Nevanlinna
Journal:  J Med Genet       Date:  2012-05-31       Impact factor: 6.318

7.  BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.

Authors:  Kristiina Tamboom; Krista Kaasik; Jelena Aršavskaja; Mare Tekkel; Aili Lilleorg; Peeter Padrik; Andres Metspalu; Toomas Veidebaum
Journal:  Hered Cancer Clin Pract       Date:  2010-04-09       Impact factor: 2.857

8.  Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.

Authors:  Johanna I Kiiski; Liisa M Pelttari; Sofia Khan; Edda S Freysteinsdottir; Inga Reynisdottir; Steven N Hart; Hermela Shimelis; Sara Vilske; Anne Kallioniemi; Johanna Schleutker; Arto Leminen; Ralf Bützow; Carl Blomqvist; Rosa B Barkardottir; Fergus J Couch; Kristiina Aittomäki; Heli Nevanlinna
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

Review 9.  Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.

Authors:  Carlos Andrés Ossa; Diana Torres
Journal:  Oncologist       Date:  2016-06-10

10.  BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.

Authors:  Henriette Roed Nielsen; Mef Nilbert; Janne Petersen; Steen Ladelund; Mads Thomassen; Inge Søkilde Pedersen; Thomas V O Hansen; Anne-Bine Skytte; Åke Borg; Christina Therkildsen
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.